Prostate cancer: Medicoeconomic aspects;Cancer de la prostate : aspects médicoéconomiques

Progres en Urologie

Volumn 20, Issue 2, 2010, Pages 85-90

  Kanso, C ^a   Etner, J ^b   Debre B ^a   Zerbib, M ^a  

^a université Paris Descartes ^*  (France)

^b et Institut de recherche et documentation en économie de la santé   (France)

Author keywords

Costs; Economic aspects; Prostate cancer; Public health

Indexed keywords

COST BENEFIT ANALYSIS; ECONOMICS; EMPLOYMENT; FRANCE; HUMAN; INCIDENCE; LAPAROSCOPY; MALE; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PROSTATE TUMOR; PUBLISHING; QUALITY OF LIFE; REVIEW;

COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; EMPLOYMENT; FRANCE; HUMANS; INCIDENCE; LAPAROSCOPY; MALE; PROSTATIC NEOPLASMS; PUBLISHING; QUALITY OF LIFE;

EID: 75149181283     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.purol.2009.06.007     Document Type: Short Survey

References (34)

1. Belot A., Grosclaude P., Bossard N., Jougla E., Benhamou E., Delafosse P., et al. Incidence et mortalité des cancers en France durant la période 1980-2005. Rev Epidemiol Santé Publique 56 3 (2008) 159-175
2. Moore R., Mao Y., Zhang J., and Clarke K. Economic burden of illness in Canada (1993) (1997), Health Canada, Ottawa
3. Hodgson T.A. The state of the art of cost-of-illness estimates. Adv Health Econ Health Serv Res 4 (1983) 129-164
4. Denmeade S.R., and Isaacs J.T. Prostate cancer: Where are we and where are we going?. Br J Urol 79 Suppl. 1 (1997) 2-7
5. Taplin S.H., Barlow W., Urban N., Mandelson M.T., Timlin D.J., Ichikawa L., et al. Stage, age, comorbidity, and direct cost of colon, prostate, and breast cancer care. J Natl Cancer Inst 87 (1995) 417-426
6. Sennfält K, Carlsson P, Varenhorst E. Diffusion and economic consequences of health technologies in prostate cancer care in Sweden, 1991-2002. Eur Urol 2006;9(6):1028-34.
7. Amling CL. Biochemical recurrence after localized treatment. Urol Clin North Am 2006;33(2):147-59 [v].
8. Durand-Zaleski I. Aspects économiques et politiques de la prévention du cancer de la prostate. Prog Urol 18 Suppl. 2 (2008) S66-S68
9. Thompson I.M., Goodman P.J., Tangen C.M., Lucia M.S., Miller G.J., Ford L.G., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 (2003) 215-224
10. Hamdy F.C., and Rouprêt M. L'étude PCPT. Prog Urol 18 Suppl. 3 (2008) S40-S43
11. Zeliadt S.B., Etzioni R.D., Penson D.F., Thompson I.M., and Ramsey S.D. Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer. Am J Med 118 (2005) 850-857
12. Soulié M., Beuzeboc P., Cornud F., et al. Recommandations en onco-urologie: cancer de la prostate. Prog Urol 17 (2007) 1157-1188
13. Haillot O., Villers A., Soulie M., and Baron J.-C. Dépistage du cancer de la prostate (IV). Approche économique : les coûts des tests de dépistage et des traitements. Prog Urol 8 (1998) 517-523
14. Andriole G.L., Grubb III R.L., Buys S.S., et al. Mortality results from a randomized prostrate cancer screening trial. N Engl J Med 360 (2009) 1310-1319
15. Schroder F.H., Hugosson J., Roobol M.J., et al. Screening and prostate cancer mortality in a randomized European study. N Engl J Med 360 (2009) 1320-1328
16. Kobayashi T., Goto R., Ito K., and Mitsumori K. Prostate cancer screening strategies with rescreening interval determined by individual baseline prostate-specific antigen value are cost-effective. Eur J Surg Oncol 33 6 (2007) 783-789
17. Anderson J.K., Murdock A., Cadeddu J.A., and Lotan Y. Cost comparison of laparoscopic versus radical retropubic prostatectomy. Urology 66 3 (2005) 557-560
18. Mouraviev V. Financial comparative analysis of minimally invasive surgery to open surgery for localized prostate cancer: a single-institution experience. Urology 69 2 (2007) 311-314
19. Lotan Y., Cadeddu J.A., and Gettman M.T. The new economics of radical prostatectomy: cost comparison of open, laparoscopic and robot-assisted techniques. J Urol 172 (2004) 1431-1435
20. Scales Jr. C.D., Jones P.J., Eisenstein E.L., et al. Local cost structures and the economics of robot-assisted radical prostatectomy. J Urol 174 (2005) 2323-2329
21. Steinberg P.L., Merguerian P.A., Bihrle III W., Heaney J.A., and Seigne J.D. A da Vinci robot system can make sense for a mature laparoscopic prostatectomy program. JSLS 12 1 (2008) 9-12
22. Bauvin E., Molinier L., et al. Coût et efficacité des stratégies de prise en charge thérapeutiques du cancer localisé de prostate : étude de faisabilité en population générale. Prog Urol 13 (2003) 618-623
23. Norderhaug I., Dahl O., et al. Brachytherapy for prostate cancer: A systematic review of clinical and cost-effectiveness. Eur Urol 44 (2003) 40-46
24. Brandeis J., Pashos C.L., Henning J.M., and Litwin M.S. A nationwide charge comparison of the principal treatments for early-stage prostate carcinoma. Cancer 89 8 (2000) 1792-1799
25. Buron C., Le Vu B., Cosset J.M., Pommier P., Peiffert D., Delannes M., et al. Brachytherapy versus prostatectomy in localized prostate cancer: results of a French multicenter prospective medicoeconomic study. Int J Radiat Oncol Biol Phys 67 3 (2007) 812-822
26. Makhlouf AA, Boyd JC, Chapman TN, Theodorescu D. Perioperative costs and charges of prostate brachytherapy and prostatectomy. Urology 2002;60(4):656-60.
27. Bayoumi A.M., Brown A.D., and Garber A.M. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. J Natl Cancer Inst 92 21 (2000) 1731-1739
28. Weight C.J., Klein E.A., and Jones J.S. Androgen deprivation falls as orchiectomy rates rise after changes in reimbursement in the US Medicare population. Cancer 112 10 (2008) 2195-2201
29. Konski A., Watkins-Bruner D., Brereton H., Feigenberg S., and Hanks G. Long-term hormone therapy and radiation is cost-effective for patients with locally advanced prostate carcinoma. Cancer 106 1 (2006) 51-57
30. Rosen S. Valuing health risk. Am Econ Rev 71 (1981) 241-245
31. Johansson P.-O. Evaluating health risks: An economic approach (1995), Cambridge University Press, Cambridge
32. Jones-Lee M.W. The value of changes in the probability of death or injury. J Pol Economy 82 (1974) 835-849
33. Conley B.C. The value of human life in the demand for safety. Am Econ Rev 66 1 (1976) 45-55
34. Analyse économique des coûts du cancer en France. Sous la direction de Franck Amalric. Institut national du cancer, 2007.